|
FDA Advisory Committee recommends approval of Pfizer's proposed biosimilar to Epogen® / Procrit® across all indications
|
25 May 2017 |
|
Sangamo Therapeutics and Pfizer announce collaboration for Hemophilia A gene therapy
|
11 May 2017 |
|
Pfizer unveils ATLAS®, an interactive, user-friendly website that provides global antibiotic resistance surveillance data across 60 countries
|
21 April 2017 |
|
XELJANZ® (tofacitinib citrate) receives marketing authorisation in the European Union for the treatment of moderate to severe active rheumatoid arthritis
|
27 March 2017 |
|
The Union for International Cancer Control and Pfizer announce next phase of global grants initiative supporting metastatic breast cancer patients
|
09 March 2017 |
|
Ronald E. Blaylock elected to Pfizer's Board of Directors
|
24 February 2017 |
|
Relationship expert teams up with Pfizer to address intimacy and relationship issues for people living with chronic diseases
|
10 February 2017 |
|
Pfizer reports fourth-quarter and full-year 2016 results
|
31 January 2017 |
|
Pfizer announces expansion of ASPIRE awards program for 2017 to include $5.5M in funding for breast and hematologic cancers
|
14 December 2016 |
|
IBM and Pfizer to accelerate immuno-oncology research with Watson for Drug Discovery
|
02 December 2016 |
|
Pfizer's Prevenar 13® receives approval for use in infants and children in China
|
02 November 2016 |
|
Pfizer awarded grant to evaluate vaccine to protect newborns against group B Streptococcus infection
|
19 October 2016 |
|
Pfizer decides remaining one company best positions company to maximize future value creation
|
26 September 2016 |
|
Pfizer launches new "Moodivator" app to help support, encourage and motivate people with depression
|
14 September 2016 |
|
Pfizer appoints chief scientific officer for neuroscience research
|
08 September 2016 |
|
Pfizer to acquire small molecule anti-infective business from AstraZeneca
|
24 August 2016 |
|
Pfizer announces publication of new analysis showing long-term therapy with VYNDAQEL (tafamidis) slowed progression of rare neurodegenerative disease
|
12 August 2016 |
|
Pfizer aims to become industry leader in gene therapy with acquisition of Bamboo Therapeutics, Inc.
|
02 August 2016 |
|
Pfizer receives World Health Organization prequalification for multi-dose vial presentation of Prevenar 13®
|
19 July 2016 |
|
Merck and Pfizer initiate Phase III trial to evaluate Avelumab as first-line treatment for ovarian cancer
|
07 July 2016 |